Ritonavir 100 Mg

1 INDICATIONS AND USAGE Ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Ritonavir tablets are HIV protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. ( 1 ).

2 DOSAGE AND ADMINISTRATION Adult patients: 600 mg twice-daily with meals. ( 2.3 ) Pediatrics patients: The recommended twice daily dose for children greater than one month of age is based on body surface area and should not exceed 600 mg twice daily with meals. ( 2.4 , 5.2 ) Ritonavir oral solution should not be administered to neonates before a postmenstrual age (first day of the mother's last menstrual period to birth plus the time elapsed after birth) of 44 weeks has been attained. ( 2.4 , 5.2 ) Ritonavir oral powder can only be used for dosing increments of 100 mg. ( 2.4 ) Dose modification for ritonavir is necessary when used with other protease inhibitors. ( 2.6 ) 2.1 General Administration Recommendations Ritonavir must be used in combination with other antiretroviral agents. Ritonavir is administered orally. Ritonavir tablets should be swallowed whole, and not chewed, broken or crushed. Take ritonavir with meals. General Dosing Guidelines: Patients who take the 600 mg twice daily soft gel capsule ritonavir dose may experience more gastrointestinal side effects such as nausea, vomiting, abdominal pain or diarrhea when switching from the soft gel capsule to the tablet formulation because of greater maximum plasma concentration (Cmax) achieved with the tablet formulation relative to the soft gel capsule [see Clinical Pharmacology ( 12.3 )] . Patients should also be aware that these adverse events (gastrointestinal or paresthesias) may diminish as therapy is continued. 2.3 Dosage Recommendations in Adults Recommended Dosage for Treatment of HIV-1: The recommended dosage of ritonavir is 600 mg twice daily by mouth to be taken with meals. Use of a dose titration schedule may help to reduce treatment-emergent adverse events while maintaining appropriate ritonavir plasma levels. Ritonavir should be started at no less than 300 mg twice daily and increased at 2 to 3 day intervals by 100 mg twice daily. The maximum dose of 600 mg twice daily should not be exceeded upon completion of the titration [see Dosage and Administration ( 2.6 )] . Pregnant Women: Ritonavir oral solution is not recommended during pregnancy due to its ethanol content. Ritonavir oral solution contains the excipients ethanol (approx. 43% v/v) and propylene glycol (approx. 27% w/v) [see Use in Specific Populations ( 8.1 )] . 2.4 Dosage Recommendations in Pediatric Patients Ritonavir must be used in combination with other antiretroviral agents [see Dosage and Administration ( 2 )] . The recommended dosage of ritonavir in pediatric patients older than 1 month is 350 to 400 mg per m 2 twice daily by mouth to be taken with meals and should not exceed 600 mg twice daily. Ritonavir should be started at 250 mg per m 2 twice daily and increased at 2 to 3 day intervals by 50 mg per m 2 twice daily. If patients do not tolerate 400 mg per m 2 twice daily due to adverse events, the highest tolerated dose may be used for maintenance therapy in combination with other antiretroviral agents, however, alternative therapy should be considered [see Dosage and Administration ( 2.6 )] . Pediatric Dosage Guidelines for Oral Solution Ritonavir oral solution should not be administered to neonates before a postmenstrual age (first day of the mother's last menstrual period to birth plus the time elapsed after birth) of 44 weeks has been attained [see Warnings and Precautions ( 5.2 )] . Ritonavir oral solution contains the excipients ethanol (approx. 43% v/v) and propylene glycol (approx. 27% w/v). Special attention should be given to accurate calculation of the dose of ritonavir, transcription of the medication order, dispensing information and dosing instructions to minimize the risk for medication errors, and overdose. This is especially important for young children. Total amounts of ethanol and propylene glycol from all medicines that are to be given to pediatric patients 1 to 6 months of age should be taken into account in order to avoid toxicity from these excipients [see Warnings and Precautions ( 5.2 ) and Overdosage ( 10 )] . When possible, dose should be administered using a calibrated dosing syringe. Table 1. Pediatric Dosage Guidelines for Oral Solution * * The concentration of the oral solution is 80 mg per mL. Body Surface Area (m 2 ) Twice Daily Dose 250 mg per m 2 Twice Daily Dose 300 mg per m 2 Twice Daily Dose 350 mg per m 2 Twice Daily Dose 400 mg per m 2 0.20 0.6 mL (50 mg) 0.75 mL (60 mg) 0.9 mL (70 mg) 1.0 mL (80 mg) 0.25 0.8 mL (62.5 mg) 0.9 mL (75 mg) 1.1 mL (87.5 mg) 1.25 mL (100 mg) 0.50 1.6 mL (125 mg) 1.9 mL (150 mg) 2.2 mL (175 mg) 2.5 mL (200 mg) 0.75 2.3 mL (187.5 mg) 2.8 mL (225 mg) 3.3 mL (262.5 mg) 3.75 mL (300 mg) 1.00 3.1 mL (250 mg) 3.75 mL (300 mg) 4.4 mL (350 mg) 5 mL (400 mg) 1.25 3.9 mL (312.5 mg) 4.7 mL (375 mg) 5.5 mL (437.5 mg) 6.25 mL (500 mg) 1.50 4.7 mL (375 mg) 5.6 mL (450 mg) 6.6 mL (525 mg) 7.5 mL (600 mg) Body surface area (BSA) can be calculated as follows 1 : Pediatric Dosage Guidelines for Oral Powder: Ritonavir oral powder should be used only for dosing increments of 100 mg. Ritonavir powder should not be used for doses less than 100 mg or for incremental doses between 100 mg intervals. Ritonavir oral solution is the preferred formulation for patients requiring doses less than 100 mg or incremental doses between 100 mg intervals . 2.6 Dose Modification due to Drug Interaction Dose reduction of ritonavir is necessary when used with other protease inhibitors: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. Prescribers should consult the full prescribing information and clinical study information of these protease inhibitors if they are co-administered with a reduced dose of ritonavir [see Warnings and Precautions ( 5.1 ) , and Drug Interactions ( 7 )] . Image

6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling. Drug Interactions [see Warnings and Precautions ( 5.1 )] Hepatotoxicity [see Warnings and Precautions ( 5.3 )] Pancreatitis [see Warnings and Precautions ( 5.4 )] Allergic Reactions/Hypersensitivity [see Warnings and Precautions ( 5.5 )] When co-administering ritonavir with other protease inhibitors, see the full prescribing information for that protease inhibitor including adverse reactions. The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Cipla Ltd., India at 1-866-604-3268 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Adults The safety of ritonavir alone and in combination with other antiretroviral agents was studied in 1,755 adult patients. Table 2 lists treatment-emergent Adverse Reactions (with possible or probable relationship to study drug) occurring in greater than or equal to 1% of adult patients receiving ritonavir in combined Phase II/IV studies. The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia. Table 2. Treatment-Emergent Adverse Reactions (With Possible or Probable Relationship to Study Drug) Occurring in greater than or equal to 1% of Adult Patients Receiving Ritonavir in Combined Phase II/IV Studies (N = 1,755) Adverse Reactions n % Eye disorders Blurred vision 113 6.4 Gastrointestinal Disorders Abdominal Pain (upper and lower) * 464 26.4 Diarrhea including severe with electrolyte imbalance * 1,192 67.9 Dyspepsia 201 11.5 Flatulence 142 8.1 Gastrointestinal hemorrhage * 41 2.3 Gastroesophageal reflux disease (GERD) 19 1.1 Nausea 1,007 57.4 Vomiting * 559 31.9 General disorders and administration site conditions Fatigue including asthenia * 811 46.2 Hepatobiliary Disorders Blood bilirubin increased (including jaundice) * 25 1.4 Hepatitis (including increased AST, ALT, GGT) * 153 8.7 Immune system disorders Hypersensitivity including urticaria and face edema * 114 8.2 Metabolism and nutrition disorders Edema and peripheral edema* 110 6.3 Gout* 24 1.4 Hypercholesterolemia * 52 3.0 Hypertriglyceridemia * 158 9.0 Lipodystrophy acquired * 51 2.9 Musculoskeletal and connective tissue disorders Arthralgia and back pain * 326 18.6 Myopathy/creatine phosphokinase increased * 66 3.8 Myalgia 156 8.9 Nervous system disorders Dizziness* 274 15.6 Dysgeusia * 285 16.2 Paresthesia (including oral paresthesia) * 889 50.7 Peripheral neuropathy 178 10.1 Syncope * 58 3.3 Psychiatric disorders Confusion* 52 3.0 Disturbance in attention 44 2.5 Renal and urinary disorders Increased urination * 74 4.2 Respiratory, thoracic and mediastinal disorders Coughing* 380 21.7 Oropharyngeal Pain * 279 15.9 Skin and subcutaneous tissue disorders Acne* 67 3.8 Pruritus * 214 12.2 Rash (includes erythematous and maculopapular)* 475 27.1 Vascular Disorders Flushing, feeling hot* 232 13.2 Hypertension* 58 3.3 Hypotension including orthostatic hypotension* 30 1.7 Peripheral Coldness * 21 1.2 *Represents a medical concept including several similar MedDRA PTs Laboratory Abnormalities in Adults Table 3 shows the percentage of adult patients who developed marked laboratory abnormalities. Table 3. Percentage of Adult Patients, by Study and Treatment Group, with Chemistry and Hematology Abnormalities Occurring in greater than 3% of Patients Receiving Ritonavir Study 245 Naive Patients Study 247 Advanced Patients Study 462 PI-Naive Patients Variable Limit Ritonavir plus ZDV Ritonavir ZDV Ritonavir Placebo Ritonavir plus Saquinavir Chemistry High Cholesterol > 240 mg/dL 30.7 44.8 9.3 36.5 8.0 65.2 CPK > 1,000 IU/L 9.6 12.1 11.0 9.1 6.3 9.9 GGT > 300 IU/L 1.8 5.2 1.7 19.6 11.3 9.2 SGOT (AST) > 180 IU/L 5.3 9.5 2.5 6.4 7.0 7.8 SGPT (ALT) > 215 IU/L 5.3 7.8 3.4 8.5 4.4 9.2 Triglycerides > 800 mg/dL 9.6 17.2 3.4 33.6 9.4 23.4 Triglycerides > 1,500 mg/dL 1.8 2.6 - 12.6 0.4 11.3 Triglycerides Fasting > 1,500 mg/dL 1.5 1.3 - 9.9 0.3 - Uric Acid > 12 mg/dL - - - 3.8 0.2 1.4 Hematology Low Hematocrit < 30% 2.6 - 0.8 17.3 22.0 0.7 Hemoglobin < 8.0 g/dL 0.9 - - 3.8 3.9 - Neutrophils ≤ 0.5 x 10 9 /L - - - 6.0 8.3 - RBC < 3.0 x 10 12 /L 1.8 - 5.9 18.6 24.4 - WBC < 2.5 x 10 9 /L - 0.9 6.8 36.9 59.4 3.5 - Indicates no events reported. Adverse Reactions in Pediatric Patients Ritonavir has been studied in 265 pediatric patients greater than 1 month to 21 years of age. The adverse event profile observed during pediatric clinical trials was similar to that for adult patients. Vomiting, diarrhea, and skin rash/allergy were the only drug-related clinical adverse events of moderate to severe intensity observed in greater than or equal to 2% of pediatric patients enrolled in ritonavir clinical trials. Laboratory Abnormalities in Pediatric Patients The following Grade 3 to 4 laboratory abnormalities occurred in greater than 3% of pediatric patients who received treatment with ritonavir either alone or in combination with reverse transcriptase inhibitors: neutropenia (9%), hyperamylasemia (7%), thrombocytopenia (5%), anemia (4%), and elevated AST (3%). 6.2 Postmarketing Experience The following adverse events (not previously mentioned in the labeling) have been reported during post-marketing use of ritonavir. Because these reactions are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to ritonavir exposure. Body as a Whole Dehydration, usually associated with gastrointestinal symptoms, and sometimes resulting in hypotension, syncope, or renal insufficiency has been reported. Syncope, orthostatic hypotension, and renal insufficiency have also been reported without known dehydration. Co-administration of ritonavir with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system. Cardiovascular System First-degree AV block, second-degree AV block, third-degree AV block, right bundle branch block have been reported [see Warnings and Precautions ( 5.6 )] . Cardiac and neurologic events have been reported when ritonavir has been co-administered with disopyramide, mexiletine, nefazodone, fluoxetine, and beta blockers. The possibility of drug interaction cannot be excluded. Endocrine System Cushing's syndrome and adrenal suppression have been reported when ritonavir has been co-administered with fluticasone propionate or budesonide. Nervous System There have been postmarketing reports of seizure. Also, see Cardiovascular System. Renal and Urinary Disorders Nephrolithiasis Skin and subcutaneous tissue disorders Toxic epidermal necrolysis (TEN) has been reported.

12.3 Pharmacokinetics The pharmacokinetics of ritonavir have been studied in healthy volunteers and HIV-infected patients (CD4 greater than or equal to 50 cells per µL). See Table 5 for ritonavir pharmacokinetic characteristics. Absorption The absolute bioavailability of ritonavir has not been determined. After a 600 mg dose of oral solution, peak concentrations of ritonavir were achieved approximately 2 hours and 4 hours after dosing under fasting and non-fasting (514 KCal; 9% fat, 12% protein, and 79% carbohydrate) conditions, respectively. Ritonavir tablets are not bioequivalent to ritonavir capsules. Under moderate fat conditions (857 kcal; 31% fat, 13% protein, 56% carbohydrates), when a single 100 mg ritonavir dose was administered as a tablet compared with a capsule, AUC(0-∞) met equivalence criteria but mean Cmax was increased by 26% (92.8% confidence intervals: ↑15 to ↑39%). No information is available comparing ritonavir tablets to ritonavir capsules under fasting conditions. After administration of a single 100 mg dose under fed conditions (617 Kcal, 29% calories from fat), ritonavir oral powder demonstrated comparable bioavailability to the oral solution. Effect of Food on Oral Absorption The bioavailability of ritonavir tablet, oral solution, and oral powder is decreased under fed conditions as compared to fasted conditions. Following the administration of a 100 mg tablet dose of ritonavir, Cmax and AUCinf of ritonavir were decreased by 21 to 23% under moderate fat (857 Kcal, 30% from fat) or high fat conditions (917 Kcal, 60% calories from fat) relative to fasting conditions. Following the administration of a 600 mg dose ritonavir oral solution, Cmax and AUCinf of ritonavir were decreased by 23% and 7%, respectively, under nonfasting conditions (514 Kcal, 10% from fat) relative to fasting conditions. Dilution of the oral solution, within one hour of administration, with 240 mL of chocolate milk, Advera® or Ensure® did not significantly affect the extent and rate of ritonavir absorption. Following the administration of a 100 mg dose of ritonavir oral powder, Cmax and AUCinf of ritonavir were decreased by 23 to 49% under moderate fat (617 Kcal, 29% calories from fat) or high fat conditions (917 Kcal, 60% calories from fat) relative to fasting conditions. Metabolism Nearly all of the plasma radioactivity after a single oral 600 mg dose of 14C-ritonavir oral solution (n = 5) was attributed to unchanged ritonavir. Five ritonavir metabolites have been identified in human urine and feces. The isopropylthiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of parent drug; however, the concentrations of this metabolite in plasma are low. In vitro studies utilizing human liver microsomes have demonstrated that cytochrome P450 3A (CYP3A) is the major isoform involved in ritonavir metabolism, although CYP2D6 also contributes to the formation of M–2. Elimination In a study of five subjects receiving a 600 mg dose of 14C-ritonavir oral solution, 11.3 ± 2.8% of the dose was excreted into the urine, with 3.5 ± 1.8% of the dose excreted as unchanged parent drug. In that study, 86.4 ± 2.9% of the dose was excreted in the feces with 33.8 ± 10.8% of the dose excreted as unchanged parent drug. Upon multiple dosing, ritonavir accumulation is less than predicted from a single dose possibly due to a time and dose-related increase in clearance. Table 5. Ritonavir Pharmacokinetic Characteristics Parameter N Values (Mean ± SD) V β /F ‡ 91 0.41 ± 0.25 L/kg t 1/2 3 - 5 h CL/F SS† 10 8.8 ± 3.2 L/h CL/F‡ 91 4.6 ± 1.6 L/h CL R 62 < 0.1 L/h RBC/Plasma Ratio 0.14 Percent Bound* 98 to 99% ‡ Single ritonavir 600 mg dose. † SS = steady state; patients taking ritonavir 600 mg q12h. * Primarily bound to human serum albumin and alpha-1 acid glycoprotein over the ritonavir concentration range of 0.01 to 30 µg/mL. Special Populations: Gender, Race and Age No age-related pharmacokinetic differences have been observed in adult patients (18 to 63 years). Ritonavir pharmacokinetics have not been studied in older patients. A study of ritonavir pharmacokinetics in healthy males and females showed no statistically significant differences in the pharmacokinetics of ritonavir. Pharmacokinetic differences due to race have not been identified. Pediatric Patients Steady-state pharmacokinetics were evaluated in 37 HIV-infected patients ages 2 to 14 years receiving doses ranging from 250 mg per m 2 twice-daily to 400 mg per m 2 twice-daily in PACTG Study 310, and in 41 HIV-infected patients ages 1 month to 2 years at doses of 350 and 450 mg per m 2 twice-daily in PACTG Study 345. Across dose groups, ritonavir steady-state oral clearance (CL/F/m 2 ) was approximately 1.5 to 1.7 times faster in pediatric patients than in adult subjects. Ritonavir concentrations obtained after 350 to 400 mg per m 2 twice-daily in pediatric patients greater than 2 years were comparable to those obtained in adults receiving 600 mg (approximately 330 mg per m 2 ) twice-daily. The following observations were seen regarding ritonavir concentrations after administration with 350 or 450 mg per m 2 twice-daily in children less than 2 years of age. Higher ritonavir exposures were not evident with 450 mg per m 2 twice-daily compared to the 350 mg per m 2 twice-daily. Ritonavir trough concentrations were somewhat lower than those obtained in adults receiving 600 mg twice-daily. The area under the ritonavir plasma concentration time curve and trough concentrations obtained after administration with 350 or 450 mg per m 2 twice-daily in children less than 2 years were approximately 16% and 60% lower, respectively, than that obtained in adults receiving 600 mg twice daily. Renal Impairment Ritonavir pharmacokinetics have not been studied in patients with renal impairment, however, since renal clearance is negligible, a decrease in total body clearance is not expected in patients with renal impairment. Hepatic Impairment Dose-normalized steady-state ritonavir concentrations in subjects with mild hepatic impairment (400 mg twice-daily, n = 6) were similar to those in control subjects dosed with 500 mg twice-daily. Dose-normalized steady-state ritonavir exposures in subjects with moderate hepatic impairment (400 mg twice-daily, n=6) were about 40% lower than those in subjects with normal hepatic function (500 mg twice-daily, n = 6). Protein binding of ritonavir was not statistically significantly affected by mild or moderately impaired hepatic function. No dose adjustment is recommended in patients with mild or moderate hepatic impairment. However, health care providers should be aware of the potential for lower ritonavir concentrations in patients with moderate hepatic impairment and should monitor patient response carefully. Ritonavir has not been studied in patients with severe hepatic impairment. Pregnancy Based on evaluation of the published literature, ritonavir exposures are reduced during pregnancy relative to postpartum. Drug Interactions [see also Contraindications ( 4 ), Warnings and Precautions ( 5.1 ), and Drug Interactions ( 7 )] Table 6 and Table 7 summarize the effects on AUC and C max , with 95% confidence intervals (95% CI), of co-administration of ritonavir with a variety of drugs. For information about clinical recommendations see Table 4 in Drug Interactions ( 7 ) . Table 6. Drug Interactions - Pharmacokinetic Parameters for Ritonavir in the Presence of the Co-administered Drug Co-administered Drug Dose of Co-administered Drug (mg) Dose of Ritonavir (mg) N AUC % (95% CI) C max (95% CI) C min (95% CI) Clarithromycin 500 q12h, 4 d 200 q8h, 4 d 22 ￪ 12% (2, 23%) ￪ 15% (2, 28%) ￪14% (-3, 36%) Didanosine 200 q12h, 4 d 600 q12h, 4 d 12 ↔ ↔ ↔ Fluconazole 400 single dose, day 1; 200 daily, 4 d 200 q6h, 4 d 8 ￪ 12% (5, 20%) ￪ 15% (7, 22%) ￪ 14% (0, 26%) Fluoxetine 30 q12h, 8 d 600 single dose, 1 d 16 ￪ 19% (7, 34%) ↔ ND Ketoconazole 200 daily, 7 d 500 q12h, 10 d 12 ￪ 18% (-3, 52%) ￪ 10% (-11, 36%) ND Rifampin 600 or 300 daily, 10 d 500 q12h, 20 d 7, 9 1 ￬ 35% (7, 55%) ￬ 25% (-5, 46%) ￬ 49% (-14, 91%) Voriconazole 400 q12h, 1 d; then 200 q12h, 8 d 400 q12h, 9 d ↔ ↔ ND Zidovudine 200 q8h, 4 d 300 q6h, 4 d 10 ↔ ↔ ↔ ND = not determined Table 7. Drug Interactions - Pharmacokinetic Parameters for Co-administered Drug in the Presence of Ritonavir Co-administered Drug Dose of Co-administered Drug (mg) Dose of Ritonavir (mg) N AUC % (95% CI) C max (95% CI) C min (95% CI) Alprazolam 1, single dose 500 q12h, 10 d 12 ￬ 12% (-5, 30%) ￬ 16% (5, 27%) ND Avanafil 50, single dose 600 q12h 14 6 ￪ 13-fold ￪ 2.4-fold ND Clarithromycin 500 q12h, 4 d 200 q8h, 4 d 22 ￪ 77% (56, 103%) ￪ 31% (15, 51%) ￪ 2.8-fold (2.4, 3.3X) 14-OH clarithromycin metabolite ￬ 100% ￬ 99% ￬ 100% Desipramine 100, single dose 500 q12h, 12 d 14 ￪ 145% (103, 211%) ￪ 22% (12, 35%) ND 2-OH desipramine metabolite ￬ 15% (3, 26%) ￬ 67% (62, 72%) ND Didanosine 200 q12h, 4 d 600 q12h, 4 d 12 ￬ 13% (0, 23%) ￬ 16% (5, 26%) ↔ Ethinyl estradiol 50 µg single dose 500 q12h, 16 d 23 ￬ 40% (31, 49%) ￬ 32% (24, 39%) ND Fluticasone propionate aqueous nasal spray 200 mcg qd, 7 d 100 mg q12h, 7 d 18 ￪ approximately 350-fold 5 ￪ approximately 25-fold 5 Indinavir 1 Day 14 400 q12h, 15 d 400 q12h, 15 d 10 ￪ 6% (-14, 29%) ￬ 51% (40, 61%) ￪ 4-fold (2.8, 6.8X) Day 15 ￬ 7% (-22, 28%) ￬ 62% (52, 70%) ￪ 4-fold (2.5, 6.5X) Ketoconazole 200 daily, 7 d 500 q12h, 10 d 12 ￪ 3.4-fold (2.8, 4.3X) ￪ 55% (40, 72%) ND Meperidine 50 oral single dose 500 q12h, 10 d 8 ￬ 62% (59, 65%) ￬ 59% (42, 72%) ND Normeperidine metabolite 6 ￪ 47% (-24, 345%) ￪ 87% (42, 147%) ND Methadone 4 5, single dose 500 q12h, 15 d 11 ￬ 36% (16, 52%) ￬ 38% (28, 46%) ND Raltegravir 400, single dose 100 q12h, 16 d 10 ￬ 16% (-30, 1%) ￬ 24% (-45, 4%) ￬ 1% (-30, 40%) Rivaroxaban 10, single dose (days 0 and 7) 600 q12h (days 2 to 7) 12 ￪ 150% (130 to 170%) 5 ￪ 60% (40 to 70%) 5 ND Rifabutin 25- O -desacetyl 150 daily, 16 d 500 q12h, 10 d 5, ￪ 4-fold (2.8, 6.1X) ￪ 2.5-fold (1.9, 3.4X) ￪ 6-fold (3.5, 18.3X) rifabutin metabolite 11 6 ￪ 38-fold (28, 56X) ￪ 16-fold (13, 20X) ￪ 181-fold (ND) Sildenafil 100, single dose 500 twice daily, 8 d 28 ￪ 11-fold ￪ 4-fold ND Simeprevir 200 mg qd, 7 d 100 mg bid, 15 d 12 ￪ 618% (463% to 815%) 8 ￪ 370% (284% to 476%) 8 ￪ 1335% (929% to 1901%) 7 Sulfamethoxazole 3 800, single dose 500 q12h, 12 d 15 ￬ 20% (16, 23%) ↔ ND Tadalafil 20 mg, single dose 200 mg q12h ￪ 124% ↔ ND Theophylline 3 mg/kg q8h, 15 d 500 q12h, 10 d 13, 11 * ￬ 43% (42, 45%) ￬ 32% (29, 34%) ￬ 57% (55, 59%) Trazodone 50 mg, single dose 200 mg q12h, 4 doses 10 ￪ 2.4-fold ￪ 34% Trimethoprim 8 160, single dose 500 q12h, 12 d 15 ￪ 20% (3, 43%) ↔ ND Vardenafil 5 mg 600 q12h ￪ 49-fold ￪ 13-fold ND Voriconazole 400 q12h, 1 d; then 200 q12h, 8 d 400 q12h, 9 d ￬ 82% ￬ 66% 400 q12h, 1 d; then 200 q12h, 8 d 100 q12h, 9 d ￬ 39% ￬ 24% Warfarin S-Warfarin 5, single dose 400 q12h, 12 d 12 ￪ 9% (-17, 44%) 4 ￬ 9% (-16, -2%) 4 ND R-Warfarin ￬33% (-38, -27%) 4 (-38, -27%) 9 ↔ ND Zidovudine 200 q8h, 4 d 300 q6h, 4 d 9 ￬ 25% (15, 34%) ￬ 27% (4, 45%) ND ND=not determined Ritonavir and indinavir were co-administered for 15 days; Day 14 doses were administered after a 15%-fat breakfast (757 Kcal) and 9%-fat evening snack (236 Kcal), and Day 15 doses were administered after a 15%-fat breakfast (757 Kcal) and 32%-fat dinner (815 Kcal). Indinavir C min was also increased 4-fold. Effects were assessed relative to an indinavir 800 mg q8h regimen under fasting conditions. Effects were assessed on a dose-normalized comparison to a methadone 20 mg single dose. Sulfamethoxazole and trimethoprim taken as single combination tablet. 90% CI presented for R- and S-warfarin AUC and C max ratios. This significant increase in plasma fluticasone propionate exposure resulted in a significant decrease (86%) in plasma cortisol AUC. For the reference arm: n=14 for C max and AUC (0-inf), and for the test arm: n=13 for C max and n=4 for AUC (0-inf). 90% CI presented for rivaroxaban 90% CI presented for simeprevir (change in exposure presented as percentage increase) ↑ Indicates increase, ↓ indicates decrease, ↔ indicates no change. * Parallel group design; entries are subjects receiving combination and control regimens, respectively.